# Clinical Trials Data KIT - Document 49

# Minimal Stimulation Protocol Using Aromek(Letrozole) and Follitrope(recFSH) Combined With INVOCell-Low Cost IVF

## Clinical Trial: https://clinicaltrials.gov/study/NCT01058252

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Tubal factor without Hydrosalpinx\n\* Unexplained infertility with unsuccessful attempts in achieving pregnancy through timed intercourse or IUI\n\* Boarder line male factor infertility\n\* Sperm DNA Fragmentation \\< 30%\n\* Normal Uterine Cavity\n\* Normal baseline ultrasound with adequate number of primary follicles present\n\* Normal FSH and E2 on Day 3\n\* Age of the female is \\< 35 years old\n\nExclusion Criteria:\n\n\* If previous IVF or INVO attempts resulted in failed fertilisation\n\* Male partner who has difficulty in producing semen sample\n\* Very low sperm count, very low percentage of sperm motility and morphology\n\* Sperm DNA Fragmentation \\> 30%\n\* Age of female patient \\> 37 years\n\* Borderline or elevated E2 or FSH on day 3 or failed CCCT or low blood inhibin levels\n\* Poor ovarian response\n\* Hydrosalpinx\n\* Anatomic difficulties in reaching ovaries for oocyte retrieval\n\* Cervical stenosis, making embryo transfer difficult\n\* Uterine abnormalities or deformities\n\* Obesity",  
 "healthyVolunteers": true,  
 "sex": "ALL",  
 "minimumAge": "20 Years",  
"stdAges": [  
"ADULT"  
],  
 "studyPopulation": "IVF Network Centers across the country, selecting patients meeting inclusion and exclusion criteria.",

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria for the clinical trial, the presence or absence of a KIT gene mutation is not mentioned as either an inclusion or exclusion criterion. Therefore, a patient with a KIT gene mutation would still be eligible for the clinical trial, assuming they meet all other specified criteria. If there are no specific genetic criteria affecting eligibility, the patient's inclusion would depend on the listed factors, such as reproductive history, age, and baseline reproductive health indicators.